Introduction {#s1}
============

Antibiotic use is a primary driver of antibiotic resistance, and reducing antibiotic use is a central strategy for combatting resistance ([@bib19]; [@bib21]). Understanding the relationship between antibiotic use and antibiotic resistance is therefore critical for the design of rational antibiotic stewardship strategies. Multiple studies have identified cross-sectional relationships between antibiotic use and resistance, especially across European countries and US states ([@bib18]; [@bib16]; [@bib6]; [@bib3]; [@bib15]; [@bib58]; [@bib38]). In general, these studies compare total outpatient antibiotic use with population-level resistance. However, antibiotic use is generally not evenly distributed. A study of outpatient prescribing in the UK found that 30% of patients were prescribed at least one antibiotic per year, with the top 9% of patients receiving 53% of all antibiotics ([@bib51]). A study of beneficiaries of Medicare, a national health insurance program that covers that vast majority of Americans 65 and older, found that the proportion of beneficiaries who take antibiotics varies by US state and drug class ([@bib61]). In some cases, antibiotic courses can last for months or even years ([@bib14]; [@bib31]). Because antibiotic use is uneven, total use does not distinguish between broad use---many people receiving a few prescriptions---and intense use---a few people receiving many prescriptions ([@bib5]).

It stands to reason that the distribution of antibiotic use, not just total use, could have an effect on resistance ([@bib56]). There are few studies of the relationship between repeated antibiotic exposure on antibiotic resistance ([@bib12]; [@bib26]; [@bib8]; [@bib1]; [@bib42]; [@bib41]; [@bib9]), and it remains unclear whether broad use or intense use is associated with population-level resistance. For example, if a first course of antibiotics given to an antibiotic-naive patient clears most of the susceptible bacteria they carry, then a second course in the same patient will have only a small effect, since most susceptible bacteria were already eliminated. Giving that second course to a different, antibiotic-naive patient instead would have a greater effect on population-level resistance. On the other hand, multiple courses given to a single patient might have a synergistic effect on resistance.

The goal of this study was to test the hypothesis that intense antibiotic use has a stronger association with population-level resistance than broad, low-level antibiotic use. We used an ecological design to compare the distribution of antibiotic use with antibiotic resistance. Although an ecological design is potentially subject to confounders and cannot definitively test for the causal effect of the distribution of use on resistance at the individual level, ecological studies of use and resistance are the most feasible design for studying the relationship between antibiotic use and population-level resistance, and the results of ecological designs play an important role in developing antibiotic stewardship policies ([@bib28]; [@bib49]).

To test this hypothesis, we first characterized the distribution of outpatient antibiotic use in two US nationwide pharmacy prescription claims databases, Truven Health MarketScan Research Database ([@bib55]) and Medicare, both covering 2011--2014. We considered only outpatient antibiotic prescribing, which accounts for 80--90% of total medical antibiotic use in the UK and Sweden ([@bib47]; [@bib48]) and is presumed to account for a similar fraction in the US ([@bib10]). Unlike antibiotic sales data and nationwide healthcare surveys ([@bib25]), MarketScan and Medicare claims data, which have previously been used to characterize variations in antibiotic use ([@bib61]; [@bib53]; [@bib44]; [@bib2]), provide longitudinal prescribing information about individual people, and can therefore distinguish between many people getting a few prescriptions and a few people getting many prescriptions. We characterized the distribution of antibiotic use across US states by partitioning annual total use as the sum of annual first use---individuals' first pharmacy fill for an antibiotic in a calendar year---and annual repeat use---pharmacy fills beyond individuals' first ones in a calendar year. Second, we compared annual total antibiotic use with antibiotic resistance as measured in ResistanceOpen, a US nationwide sample of antibiotic susceptibility reports, for 2012--2015 (i.e. lagged by 1 year ([@bib58]; [@bib7])), evaluating the relationship between use and resistance across US states for 72 pathogen-antibiotic combinations. Finally, we evaluated whether annual first use and annual repeat use are differently associated with population-level resistance.

Results {#s2}
=======

Antibiotic use is not evenly distributed {#s2-1}
----------------------------------------

Our analysis included 99.8 million outpatient pharmacy antibiotic prescription fills among 62.4 million unique people, approximately 20% of the US population, during 2011--2014 using the MarketScan database ([@bib55]). In 2011, 34% of people received an antibiotic, and 10% of people received 57% of all antibiotic prescriptions. This distribution varied by population but was similar across data years ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). To characterize the distribution of specific antibiotics, we grouped individual antibiotic generic formulations into drug groups based on their chemical structures and mechanisms of action ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - Table 1). For all drug groups, most people had zero prescriptions for that antibiotic in a given year, but antibiotics differed in their distributions ([Figure 1](#fig1){ref-type="fig"}).

![The distribution of antibiotic use within individuals.\
Bars indicate the proportion of members in the MarketScan data with different numbers of prescription fills in 2011 for each of the drug groups. TMP/SMX: trimethoprim/sulfamethoxazole.](elife-39435-fig1){#fig1}

We next examined the distribution of antibiotic use for each drug group and US state. To quantify the distribution of antibiotic use, we labeled each antibiotic pharmacy claim as 'first' if it was the first pharmacy fill for that drug group made by that individual in that calendar year, and 'repeat' if it was a second, third, etc. fill for an antibiotic in the same drug group made by the same individual in the same calendar year. An individual's first and repeat claims in a calendar year add up to their total number of claims for that year. We then partitioned population-level annual total use, measured as pharmacy fills per 1000 members per year, into the sum of annual first use, measured as first fills per 1000 members per year, and repeat use, measured as repeat fill per 1000 members per year, for each drug group and US state. Annual first use of a drug group is equivalent to the proportion of the population taking an antibiotic in that group in that year.

Total use varied between drug groups and across states ([Figure 2](#fig2){ref-type="fig"}). Annual repeat use made up a steady one-quarter to one-third of annual total use across drugs and states, with the exception of tetracyclines, for which high repeat use was associated with young adults ([Figure 2---figure supplements 1](#fig2s1){ref-type="fig"} and [2](#fig2s2){ref-type="fig"}), probably for acne treatment. This distribution of first and repeat use is distinct from the pattern predicted by the single-parameter Poisson and geometric distributions ([Figure 2](#fig2){ref-type="fig"}), but the ratio of first use to repeat use for each drug was nearly constant across US Census regions ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Thus, the higher antibiotic use in the Southern states ([@bib61]; [@bib24]) is primarily attributable to a greater proportion of people taking antibiotics, not because those who receive antibiotics receive more of them.

![The distribution of antibiotic use across US states.\
Each point indicates first use and repeat use of a single drug group in a single US state (averaged over the data years). Points falling on the black line have three times as much first use as repeat use (i.e. repeat use is one-quarter of total use). The curves show the relationships between first use and repeat use expected from the Poisson and geometric distributions. TMP/SMX: trimethoprim/sulfamethoxazole.](elife-39435-fig2){#fig2}

Landscape of correlations between total use and resistance across pathogens and antibiotics {#s2-2}
-------------------------------------------------------------------------------------------

To verify that our antibiotic use and resistance data sources could be used to distinguish the associations of first use and repeat use with antibiotic resistance, we first measured the landscape of Spearman correlations between total use and antibiotic resistance for multiple pathogens and antibiotics ([@bib18]; [@bib16]; [@bib6]; [@bib3]; [@bib15]; [@bib58]). To measure antibiotic resistance, we used ResistanceOpen, a US nationwide sample of hospital antibiotic susceptibility reports ([@bib37]), which included resistance of 38 pathogens to 37 antibiotics in 641 antibiotic susceptibility reports from 230 organizations (hospitals, laboratories, and surveillance units) spread over 44 US states. Although most organizations contributing antibiotic susceptibility reports were hospitals, hospital antibiotic susceptibility reports are biased toward community-acquired organisms ([@bib59]; [@bib27]), community antibiotic use can drive antibiotic resistance measured in hospitals ([@bib30]; [@bib39]), and studies often compare hospital antibiotic susceptibility reports with community antibiotic use ([@bib18]; [@bib36]; [@bib23]).

Because the epidemiology and pharmacology of each pathogen-antibiotic combination is unique, each combination could have a unique use-resistance relationship ([@bib56]). We therefore aggregated antibiotic resistance into the same drug groups with which we aggregated antibiotic use ([Supplementary file 1](#supp1){ref-type="supplementary-material"} -- Table 1) and evaluated the 72 pathogen-antibiotic combinations that were adequately represented in the antibiotic resistance data (see Materials and methods). Across those 72 combinations, correlation coefficients ranged from --32% to 64% ([Figure 3](#fig3){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"} - Table 2). The strongest correlation (Spearman's *ρ* = 64%, 95% CI 41% to 80%) was between macrolide use and the proportion of *Streptococcus pneumoniae* isolates that were macrolide nonsusceptible ([Figure 4](#fig4){ref-type="fig"}). Correlation coefficients were mostly positive (median correlation coefficient 21%, IQR 8% to 34%). Use-resistance correlations involving macrolides, quinolones, and cephalosporins were more positive than those for nitrofurantoin, and correlations involving quinolones were more positive than those for trimethoprim/sulfamethoxazole (pairwise Mann-Whitney tests, two-tailed, FDR = 0.05). Coefficients were not significantly more positive for any particular pathogen.

![Correlations between total antibiotic use and resistance are biased toward positive values.\
Error bars show 95% confidence intervals. The color strip visually displays the drug groups. Statistical significance is indicated by color of the points (black, significant at FDR = 0.05, two-tailed; dark gray, significant at α = 0.05, two-tailed; light gray, not significant). TMP/SMX: trimethoprim/sulfamethoxazole. CoNS: coagulase-negative *Staphylococcus*.\
10.7554/eLife.39435.010Figure 3---source data 1.Antibiotic use data.For each data source (MarketScan or Medicare), data subset or population among MarketScan records, state (with masked ID), and drug group, annual first and repeat claims per 1000 members. Main: main data set. Children: members at most 15 years old. Days supply: first and repeat use are reported as days supply, not claims. Multiyear: among members in the data for all four data years.\
10.7554/eLife.39435.011Figure 3---source data 2.Antibiotic resistance data.For each adequately-represented pathogen and drug group (see Materials and methods) and state (with masked ID matching the antibiotic use data), the proportion of isolates collected in that state susceptible to that drug.](elife-39435-fig3){#fig3}

![Total macrolide use and macrolide resistance among *Streptococcus pneumoniae* correlate across US states.\
Labels indicate selected states. Colors indicate US Census region (red, South; light red, Midwest; gray, Northeast; black, West). Line shows unweighted linear best fit. Southern states have highest macrolide use and resistance.](elife-39435-fig4){#fig4}

Because isolates from older adults are disproportionately represented in antibiotic susceptibility reports ([@bib29]), we suspected that population-wide resistance might, in some cases, correlate better with antibiotic use among older adults. We therefore queried outpatient pharmacy antibiotic claims records from individuals 65 and older on Medicare (see Materials and methods). When antibiotic use among Medicare beneficiaries was substituted for antibiotic use as measured in the MarketScan data ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), correlation coefficients were similar ([Supplementary file 1](#supp1){ref-type="supplementary-material"} -- Tables 2 and 3). Conversely, children are the primary carriers for some pathogens (e.g. *Streptococcus pneumoniae* ([@bib17])), so we suspected that resistance might, in other cases, better correlate with children's antibiotic use. Restricting the antibiotic use data to members at most 15 years old ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) again yielded similar coefficients ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - Tables 2 and 3). Thus, the landscape of correlations we observed was mostly robust to the exact population in which antibiotic use was measured.

We also evaluated the sensitivity of the results to the measurement of antibiotic use, substituting days supply of antibiotic for number of pharmacy fills, and the geographic level of the analysis, by aggregating the Medicare use data and resistance data at the level of the 306 hospital referral regions that approximate regional health care markets ([@bib13]) ([Supplementary file 1](#supp1){ref-type="supplementary-material"} -- Tables 2 and 3). The absolute values of the correlation coefficients were slightly closer to zero when using days supply rather than fills (Wilcoxon test, two-tailed; pseudomedian difference in absolute correlation coefficient 1.9 percentage points, 95% CI 0.72 to 3.1) and substantially closer to zero when using hospital referral regions rather than states as the units of analysis (6.1 percentage points, 95% CI 3.0 to 9.1).

We finally evaluated the sensitivity of the results to the exact antibiotic resistance data ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"} -- Tables 2 and 3). First, we excluded all antibiotic susceptibility reports whose annotations indicated they include isolates exclusively from inpatient settings. Most reports include isolates from a mix of settings, so this analysis excluded only 7% of the total number of isolates from the data. Second, we included only reports whose annotations indicated their isolates were exclusively from outpatient or emergency room settings, which retained only 14% of the isolates. Correlations using the resistance data excluding inpatient-only isolates were slightly stronger than the baseline data (Wilcoxon test, two-tailed; pseudomedian difference in absolute correlation coefficient 1.1 percentage points, 95% CI 0.01 to 2.2), but correlations computed using the outpatient-only data were not systematically stronger or weaker.

Lack of evidence for more positive association with repeat use {#s2-3}
--------------------------------------------------------------

Having examined the landscape of the relationships between total use and resistance across pathogen-antibiotic combinations, we set out to test the hypothesis that repeat use has a stronger association with resistance than first use. For each pathogen-antibiotic combination, we performed a multiple regression predicting proportion nonsusceptible from first use and repeat use ([Figure 5](#fig5){ref-type="fig"}). First use and repeat use are highly correlated in some cases ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - Table 4) which will widen the confidence intervals on the regression coefficients but should not introduce bias ([@bib50]). Regression coefficients for first use were more often positive than negative (54 of 72 \[75%\]; binomial test, 95% CI 63% to 84%). That is, first use was positively associated with resistance when controlling for repeat use. In contrast, regression coefficients for repeat use were more often negative than positive (44 of 72 \[61%\]; binomial test, 95% CI 49% to 72%). That is, repeat use was negatively associated with resistance when controlling for first use.

![Repeat use tends to be negatively associated with resistance when controlling for first use.\
Each point represents a pathogen-antibiotic combination. The position of the point shows the two coefficients from the multiple regression. The units of the coefficients are proportion resistant per annual claim per 1000 people. Color indicates drug group. Error bars show 95% CIs. (**a**) All data. (**b**) Same data, showing only the center cluster of points.](elife-39435-fig5){#fig5}

We evaluated the sensitivity of this result to age group, data source, metric of antibiotic use, geographic unit of analysis, and subset of the resistance data as described above. In all cases, regression coefficients for first use in the multiple regression were more likely to be positive than negative, and regression coefficients for repeat use were more likely to be negative than positive in all but one case ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - Table 5). For certain pathogens and antibiotics, resistance could presumably accumulate in an individual over many years ([@bib8]; [@bib41]), so we also computed alternate measures of first and repeat use by considering only individuals who were included in the MarketScan data for each year of 2011--2014, and we labeled an antibiotic fill as first use only if it was the first fill for that drug group made by that individual in the entire 4-year period. In that analysis, a similar proportion of regression coefficients for first use were positive (69%, 95% CI 57% to 80%) and regression coefficients for repeat use were equally likely to be positive or negative (53%, 95% CI 41% to 65%).

Discussion {#s3}
==========

Landscape of use-resistance relationships {#s3-1}
-----------------------------------------

We used US nationwide datasets measuring antibiotic use in 60 million individuals and antibiotic resistance in 3 million bacterial isolates to analyze relationships between antibiotic use and resistance, examining 72 pathogen-antibiotic combinations simultaneously, using identical data sources and analytical methods across combinations. Although previous studies have examined multiple pathogen-antibiotic combinations, usually no more than five pathogens or antibiotics are considered at once ([@bib18]; [@bib16]; [@bib58]). We found that correlations between total use and resistance were mostly positive and that certain drugs tended to have more positive correlations, but that there was no clear pattern by organism ([@bib3]). The overall landscape of correlations was mostly robust to the age groups studied, the subset of resistance data used, and the geographic scale of the analysis, although correlations were somewhat weaker when conducting analysis at smaller geographic scales ([@bib58]; [@bib46]; [@bib40]; [@bib35]). We used outpatient antibiotic use as the predictor of resistance because 80--90% of antibiotic use occurs in the outpatient setting ([@bib10]) and because most antibiotic pressure on pathogens is due to 'bystander selection', in which the patient is treated for some reason other than an infection caused by that pathogen ([@bib54]).

The correlations we observed between total antibiotic use and population-wide antibiotic resistance were noticeably weaker than those in highly cited European studies but comparable to those from other analyses of European data. For example, for *S. pneumoniae* and macrolides, [@bib18] reported a Spearman's *ρ* of 83% and [@bib16] reported 85%, while we found 62% and [@bib58] reported a median of 56%. These studies all used similar statistical methods, so the differences in the results must be due to some other factors (e.g. data quality, range of antibiotic use, distribution of antibiotic use, or pathogen biology). Correlations between *E. coli* resistance and use of β-lactams, cephalosporins, trimethoprim/sulfamethoxazole, and quinolones were similar to those reported in studies of use and resistance in UK primary care groups ([@bib46]; [@bib40]).

The most notable difference, however, between our study and previous results from Europe is for *S. pneumoniae* and β-lactams: [@bib18] report a Spearman's *ρ* of 84%, but we found no relation (--11%, 95% CI --41% to 22%). We propose that the narrow variation in β-lactam use across US states, approximately two-fold between the highest- and lowest-using states, obscures a correlation that is more apparent in Europe, where there is a four-fold variation between the highest- and lowest-using countries ([@bib18]). Thus, our results and those from Goossens *et al*. may be consistent with respect to the underlying biology. We also note that, when reproducing the methodology from a US study ([@bib23]) of the use-resistance relationship for β-lactams and *S. pneumoniae* (dichotomizing states as high- or low-prescribing and computing the odds ratio of resistance), we find a consistent point estimate but with wider confidence intervals (1.15, 95% CI 0.75 to 1.76).

Our study design may limit the interpretability of the landscape of use-resistance relationships. First, like the leading European studies using EARS-Net and US studies using the Centers for Disease Control and Prevention Active Bacterial Core surveillance, we compare population-wide outpatient antibiotic use with antibiotic susceptibility reports from hospitals. The degree to which hospital antibiotic susceptibility reports represent community infections is debated ([@bib59]; [@bib36]). For example, if outpatient antibiotic use selects for resistance among community-acquired infections, and hospital antibiograms reflect data from community-acquired infections as well as unrelated inpatient resistance patterns, then the correlations we measure would be biased toward weaker associations. Furthermore, antibiotic use and resistance in the community setting is not completely independent of use and resistance in the hospital setting ([@bib30]), and our approach does not account for any relationship between the two.

Second, antibiotic resistance is temporally dynamic, and our cross-sectional approach assumes that antibiotic use is autocorrelated across years ([@bib33]) or that resistance changes slowly ([@bib22]). If use does cause resistance, and use and resistance changed meaningfully over the course of the study, then the correlations we measured by aggregating over all years would be biased toward weaker associations.

Third, because of the limitations in statistical power, we did not address the possibility that use of one antibiotic can select for resistance to another antibiotic ([@bib45]; [@bib60]). Notably, use of one antibiotic can select for resistance to another antibiotic if the dominant clones of that species are resistant to both ([@bib45]). In that case, if the use rates of the two drugs are correlated across states, then the apparent relationship between one drug and resistance to that drug would be biased upward. Furthermore, because the palette of antibiotic use varies by country ([@bib57]), and different pathogen strains circulate in different populations, the univariate associations we observed between use of an antibiotic and resistance to that antibiotic in the US may not be applicable in other geographies.

Finally, like in other studies of antibiotic use, we did not address patient adherence, and typical approaches to address adherence using claims data ([@bib52]) are problematic when the intended duration of treatment is not clear. The measured correlation would then be biased if, for example, poor patient adherence increased resistance and patient adherence were also correlated with antibiotic use.

Distribution of antibiotic use and antibiotic resistance {#s3-2}
--------------------------------------------------------

We described the distribution of antibiotic use across drug groups and US states, finding that 34% of the study population took an antibiotic in a year, and 10% of the population had 57% of the antibiotic fills in that year, similar to results from the UK ([@bib51]), although this distribution varied by population ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). By partitioning annual total use into annual first use and annual repeat use, we were able to show that, for each drug, annual first use makes up the majority of annual total use and that variations in annual first use explain more variance in annual total use than do variations in annual repeat use. We also found that first use tends to have a positive association with resistance when controlling for repeat use, while repeat use tends to have negative associations with resistance when controlling for first use. This result held across sensitivity analyses.

If these associations are causal, that is, if outpatient first and repeat antibiotic use select for resistance among community-acquired pathogens, then our results would imply that antibiotic resistance in the outpatient setting is due more to first use, which tended to have positive associations with resistance, than to repeat use. In contrast to proposals to focus on intense antibiotic users for combatting resistance ([@bib51]), this situation would imply that preventing marginal prescriptions among patients whose indications are borderline-appropriate or inappropriate for antibiotics may be the more effective tactic for reducing the prevalence of resistance mechanisms already established in the US.

There are limitations to the interpretability of these results. First, as mentioned above, there is a potential mismatch between the sources of the antibiotic use and antibiotic resistance data.

Second, although antibiotic use is a major driver of antibiotic resistance, the observed results may not be causal. Factors beyond antibiotic use, like population density, play a role in antibiotic resistance ([@bib21]; [@bib38]). Even if antibiotic use and resistance are causally related, it may be that resistance affects antibiotic use. For example, if resistance to a drug is high, treatment using that drug is more likely to fail, discouraging repeated use, so that high resistance lead to decreased repeat use ([@bib59]; [@bib46]; [@bib45]). Ecological studies like this one do not directly address causality, and further work is needed to distinguish between different causal pathways.

Third, the observed population-level relationships between antibiotic use and resistance need not also hold for the relationship between an individual's first and repeat antibiotic use and the risk of a resistant infection in that individual. Any comparisons between our population-level results and individual-level studies would need to account for the difference between our population-level measures of first and repeat antibiotic use and the individual-level timing of antibiotic use and measurements of resistance.

Fourth, controlling for factors beyond antibiotic use could alter the apparent relationship between antibiotic use and resistance. In particular, we speculate that controlling for patient morbidity, which we did not address in this population-level analysis, would amplify the observed result, that first use tends to have a more positive association with antibiotic resistance than repeat use. We expect that morbid individuals have more repeat antibiotic use. We also expect that morbid individuals visit the hospital more often, putting them at higher risk of antibiotic resistant infections regardless of their antibiotic use. Thus, we speculate that repeat use causes resistance and also is a predictor of morbidity, which is associated with resistance. Failing to control for morbidity thus biases the association between repeat use and resistance toward more positive values. Conversely, controlling for morbidity would decrease the measured relationships between repeat use and resistance, amplifying our central result.

Fifth, we defined first and repeat use with respect to the calendar year, while it may be that some other timescale is the appropriate one for this analysis. Although our central result held when re-defining first and repeat use with respect to a 4-year period ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - Table 5), it may be that, say, repeat use within an individual on a time-scale shorter than a year is an important determinant for risk of resistance in that individual. Our study does not distinguish between repeat use that occurs across calendar year boundaries, which is presumably important for relating individuals' antibiotic use with their risk of resistance.

Finally, we note that first use and repeat use are only one set of many ways of measuring the distribution of antibiotic use. For example, 10 repeat uses could mean 1 person with 10 repeat uses or 10 people with 1 repeat use each. The first and repeat use metrics cannot distinguish between these two cases, and it may be that some other measure of the distribution of antibiotic use would yield different results.

In conclusion, we find that population-wide antibiotic use and population-wide resistance appears to be more closely linked with broadly distributed, low-intensity use rather than with intensity of use. Ultimately, accurate models predicting the emergence and spread of antibiotic resistance will require more careful characterizations of who gets what antibiotic ([@bib20]), what selection pressure that places on pathogens, how those pathogens are transmitted, and in whom they manifest as infections ([@bib34]). An ideal study would compare the complete history of an individual's outpatient and inpatient antibiotic exposure with clinical microbiology data from that same individual, cross-referenced against population-level factors, among a representative, nationwide sample of individuals. Individual-level results could then also be compared with mechanistic models of resistance to draw inferences about within-host effects of antibiotic use ([@bib32]; [@bib11]), and the role of co-occurring resistance and correlated antibiotic use could be addressed. In the absence of such a dataset, these ecological, associative results provide a guide to the development of antibiotic stewardship policy.

Materials and methods {#s4}
=====================

Study population and antibiotic use {#s4-1}
-----------------------------------

MarketScan ([@bib55]) data covering 2011--2014 were used to identify insurance plan members and characterize their outpatient antibiotic use. To ensure quality of the antibiotic use distribution data, only members who were on their insurance plan for 12 months during a given calendar year were included. Prescription fills for oral and injected antibiotics were identified by generic formulation ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - Table 6) and drug forms ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - Table 7). We treated multiple claims on the same day for the same generic formulation with the same refill code as a single prescription fill. In the main analysis, antibiotic use was measured using fills, rather than days supply of drug, because some previous research has suggested that prescriptions better correlate with resistance ([@bib7]) and that this choice is probably not detrimental ([@bib58]; [@bib33]). Generic drugs were grouped into antibiotic drug groups designed to correspond to the antibiotic resistance drug groups described below ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - Table 1). All measures of antibiotic use were computed for each year 2011 to 2014, and the mean for each value across the 4 years was reported and used in analyses of the use-resistance relationship.

Antibiotic use among Medicare beneficiaries was measured as previously described ([@bib43]). Briefly, we considered fee-for-service beneficiaries at least 65 years old among and with 12 months of enrollment in Medicare Part B and Part D among a 20% sample of beneficiaries for each year 2011 to 2014. The Medicare data, which provides the ZIP Code for each beneficiary, were also aggregated at the level of hospital referral region ([@bib13]), using the 2011 ZIP Code to region crosswalk. MarketScan data do not include ZIP Code-level resolution.

This study was deemed exempt from review by the institutional review board at the Harvard T. H. Chan School of Public Health.

Antibiotic resistance {#s4-2}
---------------------

Antibiotic resistance prevalences for common bacterial pathogens were identified from ResistanceOpen, a previously developed database of spatially localized patterns of antibiotic resistance ([@bib37]). This continuously updated database contains antibiotic resistance data from online sources during 2012 to 2015. At the time of analysis, the resistance data consisted of approximately 86,000 records, each indicating the fraction of isolates of an organism that were nonsusceptible to a particular drug in a particular antibiotic susceptibility report ('antibiogram'). The median number of isolates corresponding to each record was 93, but records had up to 75,000 associated isolates. Seven records (\<0.01%) with missing numbers of isolates were excluded. In antibiograms that separated *S. aureus* into MRSA and MSSA, resistance of aggregate *S. aureus* to individual drugs was taken as the average of the MRSA and MSSA records, weighted by number of isolates. MRSA and MSSA were not considered as separate species in any analysis.

Antibiotics used in antibiotic resistance assays were grouped into antibiotic drug groups ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - Table 1) designed to correspond to the antibiotic use groups. If resistance to more than one antibiotic in a drug group was reported for a particular pathogen in a particular antibiogram, resistance to that drug group for that pathogen in that antibiogram was computed as the mean of the resistances measured for the antibiotics in that group, weighted by the number of isolates. The proportion of nonsusceptible isolates in a state for a particular pathogen-antibiotic combination was computed as the average of the proportions from each contributing antibiogram in that state, weighted by number of isolates.

Statistical methods {#s4-3}
-------------------

Antibiotic use and resistance were compared using Spearman correlations and multiple linear regressions. Of the 887 pathogen-antibiotic combinations present in the data, we analyzed the 72 combinations that were present in at least 34 states. This excluded 21% of the pathogen-antibiotic-antibiogram combinations. We established the cut-off for number of states because 80% power to detect a Pearson correlation coefficient of magnitude 0.55 at *α* = 0.01 under a two-sided hypothesis requires at least 34 samples. There is no straightforward power calculation methodology for Spearman correlations, so we used the Pearson power calculation as an approximation. We aggregated data across all years, rather than comparing use and resistance in each year, because of the sparsity of the resistance data: of 2767 pathogen-antibiotic-state combinations in the data, only 182 have data for all 4 years. No pathogen-antibiotic combination had more than 4 states with data for all 4 years. Confidence intervals on correlation coefficients were computed using the Fisher transformation and normal approximation method. Multiple comparisons were accounted for using the Benjamini-Hochberg false discovery rate (FDR) ([@bib4]). Multiple regressions predicted proportion of isolates nonsusceptible from first use and repeat use.
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This is a useful and important analysis of antibiotic usage and resistance patterns across US states. The authors pose a specific question as to whether first use is more closely correlated with resistance than repeat use. A strength is that they are able to explore this for a large number of drug-bug combinations.

One obvious difficulty is the definition of first and repeat use. First use per calendar year immediately looks problematic. In the Discussion section, mention is made of first use in a four-year period giving similar results, but there remains the possibility that there was previous usage prior to the observation period. It is likely that some repeat use is misclassified as first use but not vice versa. The scale of the problem could be assessed for, say, years 2, 3 and 4 by checking for usage in the previous calendar year, but this is not done.

Another obvious problem is that the usage data are for outpatients, but the resistance data are (mainly) from hospitals, and that the latter data was only a small sample of the levels of resistance. It\'s likely that the antibiotics used in hospitals are very different to those used in the outpatient setting and hence the resistances selected may vary. This concern is addressed well in the Discussion section, however, and we don\'t think there is further work that could be done apart from looking at the subset of community associated infections if those data were available. But this is a major caveat.

The key result (subsection "Lack of evidence for more positive association with repeat use") is that usage-resistance correlations across states tended to be positive for first use and negative for repeat use. The latter result appears to be unexpected and so post hoc explanations are invoked. Care is needed here. It is clearly reasonable to suggest that first use might generate resistance. Presumably subsequent use can then only generate resistance in still susceptible cases (see Introduction). And so on. But it is not clear how that process plays out in terms of generating the correlations explored here. It would have been good to have seen the authors\' expectations set out and justified (possibly using a mathematical model). That would help with interpreting the results. Certainly, the Discussion section might benefit from including something about what these conclusions mean for the modelling of resistance. For instance, from a within-host perspective, do the conclusions imply that one dose is enough to generate a resistant dominant population in a host? And that the clearance rate is low?

More generally, the statistical analyses presented are very simple. This aids transparency, but a lot more could have been looked at with more sophisticated regression modelling (never mind dynamical models). For instance, multivariable, multivariate regression applied to all bug-drug combinations simultaneously could look at drug, extensive/intensive use, bug and geographic (i.e. states) which might be resolvable by combining the data. Such an approach would have also allowed formal model selection/comparison to resolve statistically significant effects. The authors should at least comment on the potential of more advanced analyses and why they chose not to pursue these here.

In doing more to explain/unravel the trends seen, the route to resistance (e.g. mutation vs. mobile genetic element) might be considered, e.g. exploring if those with a mutational based resistance (e.g. fluoroquinolones) had stronger correlations with use -- repeat use in particular.

Obviously, this is an analysis of trends in the US. In a few places it would be good to compare the US situation to other countries (e.g. in the percentage of antibiotics used in outpatient vs. healthcare settings, perhaps the distribution of antibiotics used) and to explain more in detail the population (e.g. what percentage of the population is included and what is the Medicare population?).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"The distribution of antibiotic use and its association with antibiotic resistance\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Prabhat Jha (Senior Editor), a Reviewing Editor, and three reviewers.

The manuscript has been improved but we would still like a more effort put into addressing reviewer \#2\'s concerns below regarding hospital vs. outpatient antibiotic use. For instance, presentation of datasets showing some geographic correlation between usage in outpatient and hospital settings.

*Reviewer \#1:*

I am generally happy. The authors could have been slightly more open to looking at some of the additional analyses suggested by the reviewers in my opinion, but they make reasonable arguments about why they choose not to. The changes to the text address the issues of clarity and caveats highlighted by the reviewers.

*Reviewer \#2:*

I do not think this manuscript has been improved. The authors have responded to the reviewers\' comments, but have made only minor changes to the manuscript, even in response to the \"essential\" revisions. Those changes are largely confined to explanations, caveats and discussion; as far as I can see, they have not revised their analyses in any way.

In particular they have not been able to address in any meaningful way the mis-match between scoring antibiotic usage in outpatients but resistance in hospital patients. This seems to me to be a fundamental flaw in the analysis.

With regret, I cannot recommend this paper for publication. I do not have complete confidence in the findings.

*Reviewer \#3:*

The authors have addressed all the comments to my satisfaction.

10.7554/eLife.39435.018

Author response

> Essential revisions:
>
> This is a useful and important analysis of antibiotic usage and resistance patterns across US states. The authors pose a specific question as to whether first use is more closely correlated with resistance than repeat use. A strength is that they are able to explore this for a large number of drug-bug combinations.
>
> One obvious difficulty is the definition of first and repeat use. First use per calendar year immediately looks problematic. In the Discussion section, mention is made of first use in a four-year period giving similar results, but there remains the possibility that there was previous usage prior to the observation period. It is likely that some repeat use is misclassified as first use but not vice versa. The scale of the problem could be assessed for, say, years 2, 3 and 4 by checking for usage in the previous calendar year, but this is not done.

We agree that the definitions of "first" and "repeat" present difficulty. Each person has only one truly first use of an antibiotic in their whole lifetime. Any other definition of "first" and "repeat" must be defined with respect to some *ad hoc* time window.

That being said, our goal was to measure the association between the distribution of antibiotic use, at the population level, and antibiotic resistance, at the population level. Our results do not state that individuals who had a recent first use of antibiotics had a higher risk of an antibiotic resistance than individuals with recent non-first use. We only claim that population-level first and repeat use rates have associations with population-level resistance.

Our first-in-that-year and repeat-in-that-year use metrics were intended to characterize the distribution of antibiotic use across a population. We used those metrics because we found them easier to interpret than other measures of the distribution of antibiotic use, say, the Gini coefficient or Shannon entropy.

To clarify this point, we amended the Discussion section to point out that reasoning from the population level to the individual level is difficult because of possible ecological fallacies (subsection "Distribution of antibiotic use and antibiotic resistance") and because the first-in-a-year and repeat-in-a-year metrics are not obviously sensible at the individual level (subsection "Distribution of antibiotic use and antibiotic resistance").

> Another obvious problem is that the usage data are for outpatients, but the resistance data are (mainly) from hospitals, and that the latter data was only a small sample of the levels of resistance. It\'s likely that the antibiotics used in hospitals are very different to those used in the outpatient setting and hence the resistances selected may vary. This concern is addressed well in the Discussion section, however, and we don\'t think there is further work that could be done apart from looking at the subset of community associated infections if those data were available. But this is a major caveat.

We agree that measuring antibiotic resistance at hospitals is a key limitation, and we hope that the caveats in the Results section and Discussion section address this concern. To further emphasize this point, we expanded the note in the Discussion section and included another citation which compares the roles of the hospital and the community in the acquisition of resistant infections.

> The key result (subsection "Lack of evidence for more positive association with repeat use") is that usage-resistance correlations across states tended to be positive for first use and negative for repeat use. The latter result appears to be unexpected and so post hoc explanations are invoked. Care is needed here. It is clearly reasonable to suggest that first use might generate resistance. Presumably subsequent use can then only generate resistance in still susceptible cases (see Introduction). And so on. But it is not clear how that process plays out in terms of generating the correlations explored here. It would have been good to have seen the authors\' expectations set out and justified (possibly using a mathematical model). That would help with interpreting the results. Certainly, the Discussion section might benefit from including something about what these conclusions mean for the modelling of resistance. For instance, from a within-host perspective, do the conclusions imply that one dose is enough to generate a resistant dominant population in a host? And that the clearance rate is low?

We heartily agree that these results generate many interesting questions for follow-up. Developing causal explanations that unify the within-host and population-level and explain the observed associations is certainly one of them. However, as we are wary of including more material in a manuscript that introduces a new approach to studying the relationship between antibiotic use and resistance, new metrics, and new datasets, we followed the alternative recommendation and included some points about how these conclusions suggest modeling questions in the Discussion section.

We also do not suspect that repeat use somehow selects for susceptibility. We therefore made revisions that we hope clarify that repeat use tends to have negative regression coefficients only within a multiple regression that also includes first use as a predictor. In other words, repeat use has a negative association with resistance only when first use is controlled for. It is not the case that repeat use has a negative correlation with resistance. This is a subtle but important distinction that we tried to clarify (Results section, Discussion section).

We appreciate the cautionary note about invoking *post hoc* explanations, which, as we understand, refers to the section of the Discussion section that point outs the possibility of "reverse causality" (subsection "Distribution of antibiotic use and antibiotic resistance"). We temper this point by noting that studies with ecological designs are of limited value for distinguishing between different potential causal pathways (subsection "Distribution of antibiotic use and antibiotic resistance").

> More generally, the statistical analyses presented are very simple. This aids transparency, but a lot more could have been looked at with more sophisticated regression modelling (never mind dynamical models). For instance, multivariable, multivariate regression applied to all bug-drug combinations simultaneously could look at drug, extensive/intensive use, bug and geographic (i.e. states) which might be resolvable by combining the data. Such an approach would have also allowed formal model selection/comparison to resolve statistically significant effects. The authors should at least comment on the potential of more advanced analyses and why they chose not to pursue these here.

We agree that this data presents many opportunities for developing and testing more complex methodology to address more sophisticated questions about antibiotic use and resistance. For example, we suspect that use of antibiotic A will select for resistance B in an organism for which resistance to A and B are correlated. Methodology to address these kinds of questions is developing (see citations subsection "Landscape of use-resistance relationships"). Models with more predictors may be more accurate, but we do not have a way to verify them with the available data, and it is not clear they will directly address our central question about the association of the distribution of use with resistance.

That being said, we appreciate this suggestion and amended a section of the Discussion section to propose this more careful approach as a fruitful direction for future work.

> In doing more to explain/unravel the trends seen, the route to resistance (e.g. mutation vs. mobile genetic element) might be considered, e.g. exploring if those with a mutational based resistance (e.g. fluoroquinolones) had stronger correlations with use -- repeat use in particular.

We agree that this is an interesting idea, but we have two concerns.

First, we expect that the strength of the use-resistance relationship, whether measured by correlation or by regression, will depend on many factors related to the biology and epidemiology of the organism. The resistance mechanism is certainly one of those factors, but it could be that the relationship between quinolone use rates and quinolone resistance among *E. coli* is strong because of factors that have to do with *E. coli* alone or with quinolone use alone, rather than the mechanism of quinolone resistance in *E. coli*. In this sense, we feel the more appropriate hypothesis is that the use-resistance association for a mutational-based resistance to a drug in an organism will be stronger than the association for an HGT-based resistance for the same drug and pathogen. This strikes us as a difficult question that deserves more careful attention and a different data source. In our data sets, resistance is measured phenotypically, not genotypically, so mutational and HGT-based resistance mechanisms cannot be separated for a given drug-organism combination.

Second, we are not entirely sure that our results are consistent with this hypothesis, even when broadly stated. We found macrolides, quinolones, and cephalosporins had systematically more positive use-resistance correlations than nitrofurantoin and TMP/SMX. However, resistance mechanisms do not obviously fall along these lines. Macrolide and nitrofurantoin resistance come from a mix of mutational and HGT-based mechanisms, while cephalosporin resistance is probably plasmid-based. In some cases, quinolone resistance can be HGT-based (Jacoby, 2005). Thus, these distinctions would require a careful review of the dominant resistance mechanisms present in each organism, which is outside the scope of this manuscript.

We would appreciate further suggestions on this point if we have misconstrued the suggestion.

> Obviously, this is an analysis of trends in the US. In a few places it would be good to compare the US situation to other countries (e.g. in the percentage of antibiotics used in outpatient vs. healthcare settings, perhaps the distribution of antibiotics used) and to explain more in detail the population (e.g. what percentage of the population is included and what is the Medicare population?).

We thank the reviewers for reminding us to address a global audience. We therefore included:

i\) A note with a citation comparing the palette of antibiotics used in the US with those used in other countries (Discussion section), and noting the effect that this might have on the generalizability of our results,

ii\) clarified that the statistic about the ratio of outpatient to inpatient antibiotic use is from the UK and Sweden and is merely presumed to also apply to the US (Introduction), and

iii\) added an explanation about Medicare when it is first mentioned in the Introduction.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but we would still like a more effort put into addressing reviewer \#2\'s concerns below regarding hospital vs. outpatient antibiotic use. For instance, presentation of datasets showing some geographic correlation between usage in outpatient and hospital settings.
>
> \[...\]
>
> Reviewer \#2:
>
> I do not think this manuscript has been improved. The authors have responded to the reviewers\' comments, but have made only minor changes to the manuscript, even in response to the \"essential\" revisions. Those changes are largely confined to explanations, caveats and discussion; as far as I can see, they have not revised their analyses in any way.
>
> In particular they have not been able to address in any meaningful way the mis-match between scoring antibiotic usage in outpatients but resistance in hospital patients. This seems to me to be a fundamental flaw in the analysis.
>
> With regret, I cannot recommend this paper for publication. I do not have complete confidence in the findings.

As we understand, the principal concern is that the antibiotic use data, measured at pharmacies in the community, may not be causally linked to the resistance data, which was collected by hospitals.

To address this concern, in this revision, we also included sensitivity analyses considering changes in the resistance data, as was suggested in the previous round of review: "We don\'t think there is further work that could be done apart from looking at the subset of community associated infections if those data were available."

(Sensitivity analyses included in previous revisions only considered the sensitivity of the results to changes in the antibiotic use data.) In a minority of cases, the antibiogram records include annotations indicating whether the isolates whose susceptibility are reported in those records were collected from patients in outpatient facilities, emergency room patients, or inpatients:

67% of records in the ResistanceOpen data are not specific about the origin of the isolates, while the annotations on 20% of records indicate that they refer exclusively to inpatients, and 14% of records indicate that they refer specifically to outpatients and emergency room patients.

In the first new sensitivity analysis, we excluded resistance data from exclusively-inpatient antibiogram records. In the second analyses, we used only data from exclusively-outpatient/emergency room patients. The outpatient-only data is insufficient to achieve statistical significance for the landscape of use-resistance correlations, having at most 21 states per pathogen-drug combination, while our power calculation suggests that at least 33 states are required.

The results of these analyses are shown in

i\) Figure 3---figure supplement 1, a new figure showing the correlation landscape for these two sensitivity analyses,

ii\) Supplementary file 2 (correlation coefficients for all pathogen-antibiotic-dataset combinations),

iii\) Supplementary file 3 (comparison of the sensitivity analyses for the correlation landscape),

iv\) Supplementary file 5 (comparison of the sensitivity analyses for the multiple regressions),

v\) a new paragraph in subsection "Landscape of correlations between total use and resistance across pathogens and antibiotics", and

vi\) edits to subsection "Lack of evidence for more positive association with repeat use".

The main conclusions of the paper still hold when using these two subsets of the resistance: use-resistance correlations are more often positive than negative (and not systematically stronger or weaker than the correlations from the complete dataset), and first use regression coefficients are more often positive than repeat use coefficients.

We welcome suggestions for other kinds of analysis that improve the internal validity of these results.

We also wanted to ensure the manuscript is clear about a few points.

First, as mentioned in the previous revision, although most organizations contributing antibiotic susceptibility reports were hospitals, hospital antibiotic susceptibility reports are biased toward community-acquired organisms. The resistance data are "from hospitals", but this does not mean that the isolates are mostly from hospital-acquired infections (subsection "Landscape of correlations between total use and resistance across pathogens and antibiotics").

Second, antibiotic resistance in the hospital is not exclusively determined by hospital antibiotic use. The previous revision included a citation for a theoretical study (Knight et al.,2018) about how resistance measured in hospitals, even among inpatients, can be driven by outpatient antibiotic use (subsection "Landscape of correlations between total use and resistance across pathogens and antibiotics"). We supplement that reference with a recently-published one (MacFadden et al., 2018) about how outpatient antibiotic is a driver of ESBL production among *E. coli* in hospitals.

Third, as discussed in subsection "Landscape of use-resistance relationships", to whatever degree community use is *not* a determinant of antibiotic resistance as measured by hospitals, this mismatch should bias our results toward null conclusions (e.g., correlations not significantly different from zero). In other words, this weakens the power of the study to detect a relationship, rather than increasing the probability that it will discover a false relationship.

We heartily agree with reviewer \#2 that there is some mismatch between the use and resistance data, and we do expect this is a limitation to our findings, as laid out in the Introduction, Materials and methods section and Discussion section. As per the above points, we do not consider this mismatch a "fundamental" flaw, but we do invite critiques of the logic laid out above.
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